3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
2
Dermatologic
2
Breast
2
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
4
Melanoma
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Kidney Neoplasms
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
23
Nivolumab
20
atezolizumab
10
Specimen Handling
8
Ipilimumab
8
Cyclophosphamide
8
cabozantinib
6
Magnetic Resonance Spectroscopy
6
fludarabine
5
Sorafenib
5
sargramostim
4
Trastuzumab
4
Sunitinib
4
Bevacizumab
4
lenvatinib
3
enzalutamide
3
durvalumab
3
avelumab
3
X-Rays
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
spartalizumab
2
relatlimab
2
regorafenib
2
palbociclib
2
epacadostat
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
poly ICLC
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled